Clinical Patient Indication Guide. A practitioner reference for matching patients to the appropriate formulation by indication, cannabinoid load, and clinical need.
Complete dosing summary across the Bonner Natural Health suppository line. For escalation protocols or clinical decision support, contact Bonner Natural Health directly.
Each suppository in this line is built around a proprietary broad-spectrum phytocannabinoid base, enhanced with a cannabinoid complex formulated to match the receptor targets, inflammatory pathways, and physiological demands relevant to each patient population. No two formulations are identical.
This guide assists practitioners in matching patients to the appropriate suppository for their indication. For prescribing questions, dosing escalation, or Delta-8 advisory requirements, contact Bonner Natural Health directly.
A note on structure. This line comprises five formulations: Foundation (T1), Active Care (T2), Advanced Care (3A and 3B), and Neuro Complex (NC). Foundation is the entry-level formula and the starting point for women's health, sensitive patients, and titration. Active Care is the mid-load formula for gut-brain axis and colorectal indications. Advanced Care is the highest-load formula for serious chronic and terminal disease, offered in a non-psychoactive version (3A) and a Delta-8 version (3B). Neuro Complex is the CBG-dominant neurological formula. Formulations 3B and NC contain Delta-8 THC. At the rectal doses used in this line, patients typically report minimal to no intoxicating effect, but both formulations will still produce a positive result on a standard urine drug screen, so a written advisory is required before dispensing. Practitioners select the version based on the patient's drug testing obligations, not their diagnosis.
Treatment duration. All formulations in this line are long-course therapies. Patients should be counselled to expect a minimum initial assessment period of four weeks, with the full course of treatment running between six and twelve months. These are not short-term or acute-use products. The phytocannabinoid approach works through a natural process of ECS modulation and tissue support that requires sustained use over time. Practitioners should set appropriate patient expectations at the point of prescription to support compliance.
Foundation is the entry-level, non-psychoactive base formulation and the first formulation in the line. It is the appropriate starting point for sensitive patients, first-time suppository users, titration onto higher-load formulations, general wellness support, and the full range of hormonal, pelvic, and gynaecological women's health indications.
| Indication Category | Specific Presentations |
|---|---|
| Perimenopause | Brain fog, anxiety, mood instability, sleep disruption, cognitive symptoms, hormonal fluctuation |
| Menopause | Established menopause with night sweats, insomnia, anxiety, mood disorders, vaginal atrophy |
| Endometriosis | Confirmed or suspected endometriosis, endometrioma, adenomyosis, endometriosis-related pelvic pain |
| Pelvic Pain | Chronic pelvic pain, dysmenorrhoea, dyspareunia, pelvic inflammatory disease sequelae, interstitial cystitis, pelvic floor dysfunction |
| Hormonal Mood Disorders | PMS, PMDD, perimenopausal depression, hormonal anxiety, menstrual cycle-related mood disorders |
| Gynaecological Inflammation | Vulvodynia, vestibulodynia, vaginismus, chronic cervicitis, pelvic inflammatory disease |
| Hormonal Autoimmune Overlap | Lupus with gynaecological involvement, autoimmune oophoritis, thyroid-related hormonal disruption |
| Patient Profile | Details |
|---|---|
| ECS-Sensitive Patients | Patients who experience adverse reactions to standard cannabinoid doses including dizziness, fatigue, GI discomfort, or heightened sensitivity |
| Elderly Patients | Older adults with altered pharmacokinetics, polypharmacy considerations, frailty, or general age-related sensitivity to therapeutic agents |
| First-Time Suppository Users | Any patient naive to suppository delivery requiring an introductory dose before escalation to higher-load formulations |
| Mild Chronic Conditions | Mild inflammatory conditions, low-grade chronic pain, mild anxiety, mild sleep disruption, early-stage chronic disease, general immune support |
| Wellness and Prevention | Patients without a specific disease diagnosis seeking ECS support, general anti-inflammatory maintenance, or preventive phytocannabinoid use |
| Paediatric or Low Body Weight | Children or very low body weight adults where a reduced per-unit cannabinoid load is clinically appropriate. Confirm dose with practitioner before use. |
| Titration Gateway | Patients intended for Active Care, Advanced Care, or Neuro Complex who require a step-on entry point prior to escalation |
Active Care is the mid-load, non-psychoactive formulation. It is the formulation for gut-brain axis, colorectal, and gut mucosal indications, where direct rectal mucosal contact with target tissue is integral to the therapeutic rationale.
| Condition | Clinical Notes |
|---|---|
| Ulcerative Colitis | Active UC, UC in remission maintenance, pancolitis, left-sided colitis, proctitis. CBG:CBD ratio informed by published research suggesting colitis-related benefit at histological level. Provided for practitioner reference; not a treatment claim. |
| Crohn's Disease | Colonic Crohn's, ileocolonic Crohn's, perianal Crohn's disease, Crohn's in remission maintenance |
| Microscopic Colitis | Collagenous colitis, lymphocytic colitis |
| Indeterminate Colitis | IBD-unclassified, indeterminate colitis |
| Condition | Presentations |
|---|---|
| Irritable Bowel Syndrome | IBS-D (diarrhoea predominant), IBS-C (constipation predominant), IBS-M (mixed), post-infectious IBS |
| Bowel Dysmotility | Slow transit constipation, colonic inertia, dyssynergic defaecation, post-surgical bowel dysmotility |
| Functional Bowel Disorders | Functional constipation, functional diarrhoea, opioid-induced bowel dysfunction |
| Condition | Clinical Notes |
|---|---|
| Gut Dysbiosis | Post-antibiotic dysbiosis, SIBO-related microbiome disruption, chronic dysbiosis. Published research suggests a CBG:CBD near-equal ratio may support beneficial microbiome modulation. Provided for practitioner reference; not a treatment claim. |
| Gut Mucosal Disease | Radiation proctitis, diverticular disease, diverticulitis (recurrent), ischaemic colitis, solitary rectal ulcer syndrome |
| Colorectal Cancer Adjunctive | Colorectal cancer patients receiving adjunctive rectal cannabinoid support. Direct mucosal contact with target tissue is a key therapeutic advantage of rectal delivery. |
| Condition | Presentations |
|---|---|
| GI Autoimmune | Coeliac disease (symptomatic management), autoimmune enteropathy, gut-dominant lupus, gut-dominant scleroderma, eosinophilic oesophagitis with lower GI involvement |
| Hepatobiliary | Autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis. Systemic anti-inflammatory support via rectal absorption. |
| Condition | Presentations |
|---|---|
| Post-Surgical Gut | Recovery from colorectal surgery, colostomy/ileostomy reversal, anastomosis healing support, post-surgical mucosal healing. CBGA anti-fibrotic activity is relevant to this population. |
| Post-Infectious Gut | Post-infectious colitis, Clostridioides difficile sequelae, post-gastroenteritis bowel dysfunction |
Advanced Care is the highest-load formulation in the line and is intended for use by patients with active cancer, advanced autoimmune conditions, serious chronic inflammation, or those requiring maximum phytocannabinoid support. It is offered in two versions to protect patients who are subject to workplace, legal, or regulatory drug screening.
Two versions, one clinical category. Both 3A and 3B address the same patient population and the same indications. The only meaningful difference is the inclusion of Delta-8 in 3B. Practitioners should select the version based on the patient's drug testing obligations, not their diagnosis. 3A is the default for all patients whose circumstances are unknown or where drug screening applies. 3B (with Delta-8) is appropriate where a positive drug screen is not a concern and additional receptor engagement may offer clinical benefit.
| Category | Specific Indications |
|---|---|
| Solid Tumours | Breast, colorectal, prostate, lung, head and neck, cervical, ovarian, bladder, kidney, liver, pancreatic, stomach, oesophageal, thyroid, skin (non-melanoma), melanoma |
| Haematological Cancers | Leukaemia (AML, CLL, ALL), lymphoma (Hodgkin's, non-Hodgkin's), multiple myeloma, myelodysplastic syndrome |
| Adjunctive Oncology Support | Patients receiving chemotherapy, radiotherapy, or immunotherapy seeking phytocannabinoid adjunctive support for inflammation, pain, nausea, and immune modulation |
| Category | Specific Indications |
|---|---|
| Rheumatological | Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, SLE, Sjogren's syndrome, systemic sclerosis, mixed connective tissue disease, polymyalgia rheumatica, giant cell arteritis, dermatomyositis, polymyositis |
| Neurological Autoimmune | Multiple sclerosis, neuromyelitis optica, myasthenia gravis, Guillain-Barre syndrome, CIDP, autoimmune encephalitis |
| Gastrointestinal Autoimmune | Crohn's disease, ulcerative colitis, coeliac disease, autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, microscopic colitis |
| Endocrine Autoimmune | Hashimoto's thyroiditis, Graves' disease, type 1 diabetes, Addison's disease, autoimmune polyglandular syndrome |
| Skin Autoimmune | Psoriasis, lichen planus, vitiligo, pemphigus vulgaris, bullous pemphigoid, alopecia areata |
| Vascular Autoimmune | Vasculitis (ANCA-associated, Behcet's disease, Takayasu arteritis), antiphospholipid syndrome |
| Renal Autoimmune | IgA nephropathy, lupus nephritis, membranous nephropathy, Goodpasture syndrome |
| Other Autoimmune | Sarcoidosis, relapsing polychondritis, Still's disease, undifferentiated connective tissue disease, reactive arthritis, SAPHO syndrome, chronic fatigue syndrome with autoimmune component, mast cell activation syndrome (MCAS) |
| Tick-Borne AutoimmuneLyme | Lyme disease (acute and chronic), post-treatment Lyme disease syndrome (PTLDS), Lyme-associated autoimmune arthritis, neurological Lyme (Lyme neuroborreliosis), co-infections with Bartonella and Babesia where immune dysregulation is present. Immune modulation and systemic anti-inflammatory support via high-load phytocannabinoid delivery is the primary therapeutic rationale for this population. |
| Category | Specific Indications |
|---|---|
| Chronic Pain | Complex regional pain syndrome (CRPS), fibromyalgia, neuropathic pain, cancer pain, post-surgical chronic pain, chronic low back pain (inflammatory), failed back surgery syndrome |
| Inflammatory Conditions | Chronic systemic inflammation, metabolic inflammatory syndrome, cardiovascular disease with inflammatory burden, oxidative stress conditions |
| Immune Compromise | HIV/AIDS, post-transplant immune suppression, immunodeficiency disorders requiring immune modulation support |
| Category | Notes on 3B Selection |
|---|---|
| Active Cancer | Any active cancer diagnosis where maximum phytocannabinoid load is clinically warranted. Preferred over 3A for patients with active disease not subject to drug testing. |
| Advanced Autoimmune Disease | Severe or treatment-resistant autoimmune disease including advanced MS, refractory SLE, severe Crohn's, treatment-resistant rheumatoid arthritis, chronic Lyme disease with systemic involvement, post-treatment Lyme disease syndrome (PTLDS), and conditions with significant organ involvement. |
| Palliative and Terminal Care | Any terminal diagnosis where drug testing is not a relevant concern and maximum symptom relief is the priority. Pain, inflammation, nausea, appetite, and anxiety are all addressed by this formulation. |
| Treatment-Resistant Pain | Patients who have plateaued on 3A or other cannabinoid therapies and require escalation. Suitable for opioid reduction candidates under practitioner guidance. |
Neuro Complex is the CBG-dominant neurological formulation. It contains Delta-8 THC. At this rectal dose, patients typically report minimal to no intoxicating effect, but it will produce a positive result on a standard urine drug screen. It is the default selection for any patient whose primary indication is neurological.
Primary formulation for all neurological diagnoses. This is the default selection for any patient whose primary indication is neurological. For cancer patients with significant neurological involvement, discuss with the prescribing practitioner whether Advanced Care or Neuro Complex is the primary fit. Both formulations may be used concurrently under practitioner guidance.
| Condition | Clinical Notes |
|---|---|
| Alzheimer's Disease | All stages. CBG:CBD ratio consistent with published research including Patent US11497719. Peer-reviewed studies suggest CBDA and CBGA may support BACE-1 and AChE inhibitory activity relevant to amyloid pathology. Provided for practitioner reference; not a treatment claim. |
| Parkinson's Disease | All stages. Published research indicates CBG crosses the blood-brain barrier. Preclinical studies suggest a neuroprotective and dopaminergic neuron support profile. Provided for practitioner reference; not a treatment claim. |
| Lewy Body Dementia | Lewy body dementia, Parkinson's disease dementia, related alpha-synuclein pathologies |
| Frontotemporal Dementia | Frontotemporal dementia, primary progressive aphasia, behavioural variant FTD |
| Vascular Dementia | Post-stroke vascular dementia, small vessel disease dementia, mixed dementia |
| ALS / Motor Neurone Disease | CBN at 25mg per unit. Published molecular modelling research reports CNR1 binding at -9.4 kcal/mol. Preclinical studies suggest neuroprotective activity relevant to ALS models. Provided for practitioner reference; not a treatment claim. |
| Huntington's Disease | Huntington's disease, other polyglutamine repeat disorders |
| Multiple System Atrophy | Multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration |
| Condition | Clinical Notes |
|---|---|
| Stroke Recovery | Post-stroke rehabilitation, cerebral ischaemia recovery. Peer-reviewed research suggests CBG may support memory and neuroprotective pathways in cerebral ischaemia models. Provided for practitioner reference; not a treatment claim. |
| Traumatic Brain Injury | TBI recovery at all stages, post-concussion syndrome, chronic traumatic encephalopathy (CTE) |
| Spinal Cord Injury | Spinal cord injury with neurological sequelae, central sensitisation, spasticity |
| Post-Viral Neurological | Long COVID neurological symptoms, post-viral encephalitis, post-viral cognitive impairment, POTS with neurological involvement |
| Condition | Clinical Notes |
|---|---|
| Multiple Sclerosis | Relapsing-remitting MS, secondary progressive MS, primary progressive MS. Neurological CBG formula preferred over Advanced Care where neurological symptoms dominate. |
| Neuroinflammation | Chronic neuroinflammation of any origin, autoimmune encephalitis, neuromyelitis optica, CNS vasculitis |
| Peripheral Neuropathy | Diabetic neuropathy, chemotherapy-induced peripheral neuropathy, idiopathic peripheral neuropathy, small fibre neuropathy |
| Condition | Clinical Notes |
|---|---|
| Epilepsy | Drug-resistant epilepsy, Dravet syndrome, Lennox-Gastaut syndrome, focal onset seizures. Adjunctive to conventional anti-epileptic therapy. |
| Neuropathic Pain | Central and peripheral neuropathic pain, trigeminal neuralgia, post-herpetic neuralgia, phantom limb pain, complex regional pain syndrome (neurological) |
| Memory and Cognition | Age-related cognitive decline, mild cognitive impairment (MCI), subjective cognitive decline, chemotherapy-related cognitive impairment |
| Psychiatric with Neurological Basis | Treatment-resistant depression with neuroinflammatory component, PTSD with neurological involvement, OCD, Tourette syndrome |
Complete dosing summary across the Bonner Natural Health suppository line. For escalation protocols or clinical decision support, contact Bonner Natural Health directly.
| ID | Formulation | Delivered per Capsule | Delivered per 30 Units | Drug Screen |
|---|---|---|---|---|
| T1 | Foundation | 165mg | 4,950mg (4.95g) | Negative |
| T2 | Active Care | 340mg | 10,200mg (10.2g) | Negative |
| 3A | Advanced Care (non-Delta-8) | 455mg | 13,650mg (13.65g) | Negative |
| 3B | Advanced Care with Delta-8 Advise Patient | 475mg | 14,250mg (14.25g) | Positive |
| NC | Neuro Complex Advise Patient | 400mg | 12,000mg (12.0g) | Positive |
Every formulation in this line requires sustained use to produce meaningful clinical outcomes. The initial assessment period is four weeks. The full course of treatment for most patients will be between six and twelve months. There is no short-course or acute-use option in this line.
The body heals through a natural, incremental process. Phytocannabinoid therapy supports that process through ECS modulation, receptor engagement, and sustained anti-inflammatory activity. Patients who discontinue early are unlikely to achieve the results that continued use produces. Set this expectation clearly at the point of prescription.
Contact Bonner Natural Health directly for prescribing guidance, dosing escalation decisions, or Delta-8 advisory. Our clinical team supports practitioners in selecting the appropriate formulation and delivery route for complex or multi-indication patients.
FDA Compliance Statement. These statements have not been evaluated by the Food and Drug Administration. The products and formulations described in this document are not intended to diagnose, treat, cure, or prevent any disease. This document is intended for use by licensed healthcare practitioners only and does not constitute medical advice to patients. Phytocannabinoid products are classified as dietary supplements or topical preparations depending on formulation and jurisdiction. Practitioners are responsible for ensuring compliance with applicable federal, state, and local regulations prior to recommending these products to patients.
Clinical Reference Basis. The indication guidance, receptor mechanism references, and cannabinoid pharmacology information contained in this document are drawn from peer-reviewed clinical and preclinical research literature. Specific research areas informing individual formulations include published work on CBG:CBD ratios in inflammatory bowel disease, CBG neuroprotection in cerebral ischaemia, cannabinoid receptor binding pharmacology (CB1, CB2, TRPV1, GPR55), BACE-1 and AChE inhibition by acidic cannabinoids, and CNR1 binding affinity modelling for motor neurone disease applications. This document is a practitioner-facing clinical reference, not a promotional or advertising document, and does not constitute a medical claim or therapeutic guarantee on behalf of Bonner Biotech LLC or Bonner Natural Health.
Delta-8 Drug Screen Advisory. Formulation 3B (Advanced Care with Delta-8) and Formulation NC (Neuro Complex) contain Delta-8 THC. At the rectal doses used in this line, patients typically report minimal to no intoxicating effect; however, both formulations will produce a positive result on standard urine drug screening panels regardless of subjective effect. Practitioners dispensing these formulations are required to provide written advisory to patients prior to first use and to document this advisory in the patient record. A Certificate of Analysis (COA) is required for each batch of these formulations. Bonner Biotech LLC and Bonner Natural Health accept no liability arising from failure to comply with this advisory requirement.
Confidentiality and Intellectual Property. This document is the confidential and proprietary property of Bonner Biotech LLC. It is intended solely for use by licensed healthcare practitioners engaged in or considering a professional relationship with Bonner Natural Health. Unauthorised reproduction, distribution, or disclosure of this document or its contents to any third party without the express written consent of Bonner Biotech LLC is strictly prohibited and may constitute an infringement of intellectual property rights. © 2026 Bonner Biotech LLC. All rights reserved.